AviadoBio

Latest news and press releases

AviadoBio Announces Formation of Scientific Advisory Board

AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022

AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia

AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

ABOUT US

Learn more about our mission to transform lives and our industry-leading team

SCIENCE & DELIVERY

Find out more about how we are progressing innovative gene therapies to potentially treat neurodegenerative disease. 

CAREERS

When you join AviadoBio, you join more than just a company, you join a dedicated team with a clear mission

 

CONTACT

We’d love to hear from you. If you have an enquiry about our gene therapies, delivery systems or clinical trials please contact us using the details here